PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

Sponsor
ARJ Medical, Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05276557
Collaborator
(none)
40
1
6

Study Details

Study Description

Brief Summary

This is a multi-center, non-randomized, open label study. Subjects will be enrolled on a walk-in basis. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All children will be exposed to non-radioactive 13C-Urea with citric acid, and shall submit a stool sample.

Centers will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyzer results shall remain blinded to the investigator and treating physician. No patient management decisions should be made based on the investigational PyloPlus® UBT System.

Treating physician will prescribe a H. Pylori Stool Antigen Test to Stool test at either LabCorp or Quest Diagnostic, for the patient, which will be used for diagnostic purposes by the ordering physician.

Total duration of study is anticipated to be approximately 6 months.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: PyloPlus Urea Breath Test System
  • Diagnostic Test: Stool Antigen Test
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
Anticipated Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Indication for H. pylori testing

Walk in basis: Symptomatic patients of H. pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test (a single dose of 13C urea at 75mg in powder form, to be dissolved in potable water as the kit indicates) in addition to stool antigen test comparison.

Combination Product: PyloPlus Urea Breath Test System
System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.

Diagnostic Test: Stool Antigen Test
An antigen test performed via a laboratory to test patients' stool for H. pylori

Outcome Measures

Primary Outcome Measures

  1. Number of participants with recorded adverse events [24 hours]

    Number of participants with recorded adverse events after performing urea breath test

Secondary Outcome Measures

  1. Percentage of Agreement [7 days]

    Percentage of agreement between stool test reference standard and continuous urea breath test in assessing presence or absence of Helicobacter pylori infection

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male or female age 3-17 at the time of visit

  • Subject/Legal guardian (and subject when relevant) is willing to sing the Informed Consent/Assent Form

  • Naive to H. pylori treatment in the past 4 weeks

Exclusion Criteria:
  • Pregnant and/or lactating women

  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient of the quality of data

  • Participation in other interventional trials

  • Allergy to test substrates

  • Antibiotics taken within 4 weeks of the testing

  • Study subjects shall not consume the following items at least 1 hour prior to the PPUBT test: Mouthwash, Chewing Gum, Carbonated Beverages, Cigarette Smoke, Acetone (to simulate the effect of ketone production that may result from some diets), Alcohol, Food

  • Children 12 years and older - to be excluded after a written notification from the sponsor is received at the site that the limit of (approx.) 1/3 of the sample size was achieved for this group

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • ARJ Medical, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ARJ Medical, Inc.
ClinicalTrials.gov Identifier:
NCT05276557
Other Study ID Numbers:
  • ARJ-2022-PED
First Posted:
Mar 11, 2022
Last Update Posted:
Mar 11, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Mar 11, 2022